Feb 23,2022

Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities

Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced a partnership with Tilak Healthcare, a digital therapeutics company specializing in clinically validated medical mobile apps for chronic diseases. Under this new collaboration, both companies will combine Tilak’s OdySight® Care™ mobile app with Voluntis’ Theraxium platform to offer a vision-screening solution for patients living with cancer. This new solution will give patients of Voluntis’ digital therapeutics (DTx) platform access to OdySight® Care™ and the possibility to measure their visual health anytime and anywhere.

COLLABORATION PARTNERSHIP

#product & service

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 01,2022

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage Their Health

Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription digital therapeutics (PDT) company, have announced a collaboration on a virtual clinical trial that will study the effectiveness of two digital therapeutics. Both digital therapeutics are anticipated to have an impact on mental and physical health when used adjunctively with multidisciplinary oncology care regimens.

COLLABORATION PARTNERSHIP

#r&d

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 01,2022

New Study Finds Cancer-Related Anxiety and Depression are Costing Medicare $5B Annually

Blue Note Therapeutics announces findings of new study highlighting the financial impacts of cancer-related anxiety and depression in Medicare beneficiaries. The study, which included over 230,000 Medicare patients, found that the incremental healthcare costs of cancer-related anxiety and depression are estimated to be nearly $17,500 per patient annually. This corresponds to a greater than 75 percent premium on the cost of cancer care for patients with anxiety and depression compared to those without.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Mar 02,2022

Massachusetts General Hospital to Co-Develop VR Digital Therapeutic for Stem Cell Patients

Massachusetts General Hospital ("MGH") announced a research agreement with Rocket VR Health, an emerging digital therapeutics company developing clinically validated virtual reality therapies that enhance the quality of life of cancer patients, their families and their caregivers. The research will study the effects of daily Virtual Reality Therapy's effect on patients during their entire hospital stay. As part of the agreement, Rocket VR Health will leverage its virtual reality therapy platform to co-develop a VR digital therapeutic solution based on population-specific well-researched care interventions created by Massachusetts General Hospital.

COLLABORATION PARTNERSHIP

#r&d

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Mar 10,2022

Leben Salud becomes the first hospital to implement Kaiku Health in South America

Kaiku Health expansion around the world continues as Leben Salud becomes the first user of Kaiku Health in South America. The Argentinian hospital went live with Kaiku Health in November 2021 and currently uses the digital therapeutics platform in radiotherapy. Located in the Patagonia region in Argentina, Leben Salud treats thousands of cancer patients each month. In a region of great distances, Kaiku Health helps the clinic to bring the patients and care teams closer to each other regardless of their location. The dynamic symptom management enables early symptom detection and intervention, and the direct communication channel reduces any uncertainty patients may experience during their treatment. Kaiku Health also educates patients on their self-management strategies. All this is particularly important for patients who may not have easy access to visit their clinic.

COLLABORATION PARTNERSHIP

#institution

#pdt

#rpm

View Analyst & Ambassador Comments
Go to original news
May 01,2022

Blue Note Therapeutics and Bixink Enter Licensing Agreement for attune and DreAMLand

Blue Note Therapeutics and Bixink Therapeutics, a bio-subsidiary of KPS, today announced that the companies have entered into an exclusive licensing agreement for the commercialization of Blue Note’s prescription digital therapeutics (PDTs) in South Korea. The agreement includes attune™ and DreAMLand™, Blue Note’s lead PDTs designed to support the mental well-being of patients living with cancer.

COLLABORATION PARTNERSHIP

#institution

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 09,2022

Oncological digital therapeutics company Fosanis raises more than $10.5M

Fosanis announced today that it closed a Series A funding round worth more than $10.5 million (€10 million). Berlin, Germany-based Fosanis, which develops prescription digital therapeutics for all oncological indications, picked up investments from existing shareholder Ananada Impact Ventures, as well as new investors Debiopharm Innovation Fund, Ship2B Ventures and Equity Pitcher.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
May 10,2022

Prosperdtx to Present at BioNJ's 12th Annual BioPartnering Conference on May 10th, 2022

Prosperdtx, a leader in the emerging field of digital therapeutics providing predictive and personalized continuity of care for cancer patients, announced that management will present a corporate overview for 2022 at the BioNJ 12th Annual BioPartnering Conference on Tuesday, May 10, 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 10,2022

Kaiku Health enters a strategic partnership to further improve patient outcomes through digital patient monitoring

Kaiku Health, a leading digital therapeutics platform in cancer care, and Roche, a leading global healthcare company, are entering a strategic partnership in digital patient monitoring and management (DPMM). Kaiku Health and Roche aim to deploy digital tools to provide real-time symptom management by patients and Health Care Providers (HCPs), improve patient support, and provide personalised cancer care to cancer clinics and patients globally.

COLLABORATION PARTNERSHIP

#product & service

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 18,2022

Prosperdtx Launches Strategic Collaboration With Health Equity Researchers and Seqster to Improve Health Equity for Cancer Patients

Prosperdtx™, a leader in the emerging field of digital therapeutics providing predictive and personalized continuity of care for cancer patients, announced today that it will be collaborating with health equity researchers from the Office of Minority Health & Health Disparities Research at the Georgetown University Lombardi Comprehensive Cancer Center and Seqster, the leader in patient-centric healthcare technology, to empower patients with real-time access to their health data enabling supportive care for cancer patients and survivors in Washington DC’s medically underserved communities.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY